Laboratory monitoring of hemophilia A treatments: new challenges.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2019000849
Abstract: Monitoring factor VIII (FVIII) activity has traditionally been complicated by discrepancies between assays for the various sorts of FVIII molecules. The advent of novel nonfactor therapies (emicizumab, fitusiran, and anti-tissue factor pathway inhibitor antibodies) in… read more here.
Keywords: treatments new; hemophilia treatments; monitoring hemophilia; laboratory monitoring ... See more keywords